Cancer biomarker HER-2/neu in breast cancer in Indian women
This paper has been retracted.
Rajeev Singhai1, Amit V Patil2, Vinayak W Patil1
1Department of Biochemistry, Grant Medical College and Sir J J Group of Hospitals, Mumbai, India; 2Department of General Surgery, Government Medical College, Miraj, Maharashtra, India
Aim and objectives: In Indian women with breast cancer, the HER-2/neu gene is amplified in 30% of cases. Elevated serum HER-2/neu levels have been shown to be associated with a poor clinical prognosis and decreased survival in early stage breast cancer patients, and testing for this may help to manage the disease. The present study was therefore to estimate serum HER-2/neu levels in breast cancer patients and associate these with other prognostic factors.
Materials and methods: Serum HER-2/neu levels were studied in 207 patients with breast cancer, 15 with benign breast diseases, (BBD) and 175 age-matched healthy controls. Patients' age, menopausal status, node, and estrogen receptor (ER) and progesterone receptor (PgR) status were compared with serum HER-2/neu levels.
Results: Serum HER-2/neu overexpression was associated with age, disease stage and positive nodal status but not with menopausal status. Serum HER-2/neu levels were negatively correlated with hormone receptor positivity.
Conclusion: HER-2/neu serum tests should be done more frequently in Indian women with breast cancer, irrespective of their ER and PgR hormone receptor status. ELISA is a reliable and economical tool to assess the HER-2/neu status in tumors, when breast tissue samples are not available.
Keywords: breast cancer, serum HER-2/neu receptor assay, hormone receptor, ER, PgR
This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php
Other articles by this author:
Patil V, Tayade M, Pingale S, Dalvi S, Rajekar R, Deshmukh H, Patil S, Singhai R
Published Date: 11 August 2011
Patil AV, Bhamre RS, Singhai R, Tayade MB, Patil VW
Published Date: 19 April 2011
Vinayak W Patil, Rajeev Singhai, Amit V Patil, et al
Published Date: 16 March 2011
Readers of this article also read:
Prozorova GF, Pozdnyakov AS, Kuznetsova NP, Korzhova SA, Emel’yanov AI, Ermakova TG, Fadeeva TV, Sosedova LM
Published Date: 16 April 2014
Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects [Corrigendum]
Cui Y, Song Y, Wang J, Yu Z, Schuster A, Barrett YC, Frost C
Published Date: 27 March 2014
Osadnik CR, McDonald CF, Holland AE
Published Date: 25 March 2014
Ashwanikumar N, Kumar NA, Nair SA, Kumar GS
Published Date: 15 November 2012
A novel preparation method for silicone oil nanoemulsions and its application for coating hair with silicone
Hu Z, Liao M, Chen Y, Cai Y, Meng L, Liu Y, Lv N, Liu Z, Yuan W
Published Date: 12 November 2012
Deepa G, Thulasidasan AK, Anto RJ, Pillai JJ, Kumar GS
Published Date: 27 July 2012
Chen ZQ, Liu Y, Zhao JH, Wang L, Feng NP
Published Date: 30 March 2012
Schneider EW, Johnson MW
Published Date: 16 September 2011
Particle size reduction to the nanometer range: a promising approach to improve buccal absorption of poorly water-soluble drugs
Rao S, Song Y, Peddie F, Evans AM
Published Date: 20 June 2011
Espandar L, Sikder S, Moshirfar M
Published Date: 6 February 2011